Does Medicare Cover Wegovy for Heart Disease?
Medicare does not cover Wegovy (semaglutide) for heart disease treatment. Coverage remains limited to specific uses under Medicare Part D plans, excluding cardiovascular indications despite FDA approval. [1][2]
Why Isn't It Covered Yet?
Wegovy gained FDA approval in March 2024 for reducing cardiovascular death, heart attack, and stroke risk in adults with established heart disease and either obesity or overweight with weight-related conditions. However, CMS classifies it as a weight loss drug under its anti-obesity medication exclusion policy, blocking coverage for weight management—even when tied to heart benefits. Medicare Advantage plans follow the same rules. [1][3]
What Uses of Wegovy or Similar Drugs Are Covered?
Ozempic (same active ingredient) is covered for type 2 diabetes under Part D, and some plans cover Wegovy for this off-label use. Coverage varies by plan formulary, prior authorization, and step therapy requirements. Patients with heart disease but no diabetes coverage often face denials. [2][4]
When Could Coverage Change for Heart Disease?
CMS opened a National Coverage Determination (NCD) process in 2024 to review semaglutide for heart disease prevention in overweight or obese patients at high cardiovascular risk. Public comments closed in July 2024; a decision could take 6-12 months. If approved, Part D coverage would expand beyond diabetes. Medicare Advantage plans might cover sooner via supplemental benefits. [1][5]
How Do Patients Pay Without Coverage?
Cash prices for Wegovy exceed $1,300 monthly. Novo Nordisk's savings cards cap costs at $25 for 1-2 months (income-eligible up to $110,000 single/$220,000 joint). Manufacturer patient assistance programs help uninsured or low-income patients. Some appeal denials by emphasizing FDA heart approval. [2][6]
What About Other Heart Drugs or Alternatives?
Medicare covers statins, blood pressure meds, and cardiac rehab for heart disease without restrictions. For obesity-related heart risk, covered options include diabetes-approved GLP-1s like Ozempic or Mounjaro. Bariatric surgery gets coverage after failed conservative treatments. [3][4]
Sources
[1] CMS Medicare Learning Network: Semaglutide NCD Announcement
[2] Medicare.gov: Drug Coverage & Costs
[3] FDA: Wegovy Label Update for CV Risk Reduction
[4] KFF: Medicare Coverage of GLP-1s
[5] CMS: NCD Timeline
[6] Novo Nordisk: Wegovy Savings Card